CN Patent

CN110172056A — 新的氨基嘧啶衍生物

Assigned to Novartis AG · Expires 2019-08-27 · 7y expired

What this patent protects

本发明描述了新的式(I)氨基嘧啶衍生物及其药学上可接受的盐，它们似乎可以与布鲁顿氏酪氨酸激酶(Btk)相互作用。因此，所述新的氨基嘧啶类化合物可以有效地治疗自身免疫性疾病、炎性疾病、过敏性疾病、呼吸道疾病(例如哮喘和慢性阻塞性肺病(COPD))、移植排斥反应、癌症(例如血源性肿瘤或实体瘤)。

USPTO Abstract

本发明描述了新的式(I)氨基嘧啶衍生物及其药学上可接受的盐，它们似乎可以与布鲁顿氏酪氨酸激酶(Btk)相互作用。因此，所述新的氨基嘧啶类化合物可以有效地治疗自身免疫性疾病、炎性疾病、过敏性疾病、呼吸道疾病(例如哮喘和慢性阻塞性肺病(COPD))、移植排斥反应、癌症(例如血源性肿瘤或实体瘤)。

Drugs covered by this patent

Patent Metadata

Patent number: CN110172056A
Jurisdiction: CN
Classification: —
Expires: 2019-08-27
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.